News und Analysen
Should You Buy Guardant Health Before Feb. 19?
Guardant Health (NASDAQ: GH) is on the rise, in more ways than one.
Shares of the precision oncology company have skyrocketed over the last six months. Guardant Health has also chalked up several
Stock Market Today, Jan. 29: AT&T Climbs as Earnings Confirm Cash Flow Strength
AT&T (NYSE:T), a provider of wireless, broadband, and fixed-line telecom services, closed Thursday at $25.11, up 4.32%. The stock moved higher after analyst upgrades and a strong fourth-quarter 2025
AT&T's Lumen Deal Hides an Opportunity Most Investors Are Missing
Telecom giant AT&T (NYSE: T) agreed to pay $5.75 billion last year to acquire Lumen's fiber business. The deal, which is expected to close early this year, will add 4 million passed locations and 1
Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals
Despite a few setbacks, Vertex Pharmaceuticals (NASDAQ: VRTX) performed pretty well last year, although it lagged the S&P 500. However, things could be very different in 2026. Thanks to several
This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy?
Over the past five years, Novavax (NASDAQ: NVAX), a vaccine maker, lost more than 90% of its market value. Though it succeeded in its goal of launching a coronavirus vaccine, the biotech did so much
Want to Buy the Dip on Software Tech Stocks Like Palantir, Microsoft, and Oracle? Consider This BlackRock ETF.
Last year, technology outperformed the other 10 sectors of the stock market and the S&P 500, delivering a 24.7% total return. A lot of those gains were driven by semiconductor stocks like Nvidia
3 High-Yield Stocks to Buy Hand Over Fist in January
The S&P 500 index offers a paltry 1.1% dividend yield. By that standard, even consumer products giant Procter & Gamble's (NYSE: PG) 2.8% yield looks lofty. Here's why dividend lovers may want to
Why One Fund Just Bet $4 Million on Teleflex Stock Despite a 42% One-Year Drop
New York City-based Eos Management disclosed a new position in Teleflex (NYSE:TFX) as of December 31, acquiring 30,831 shares in a transaction valued at $3.76 million based on quarter-end pricing.
Should You Buy UnitedHealth Group Stock After Its Steep Sell-Off?
UnitedHealth Group (NYSE: UNH) announced its 2025 full-year and fourth-quarter results on Tuesday, Jan. 27, 2026. Despite reporting better-than-expected earnings, UnitedHealth's stock plummeted 20%.
Why I Keep Buying More Shares of This Amazing Artificial Intelligence (AI) Chip Stock for 2026
In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special
AMD and Nvidia Stock Investors Got Amazing News from China
In today's video, I discuss recent updates affecting Nvidia (NASDAQ: NVDA), Advanced Micro Devices (NASDAQ: AMD), and other AI stocks. To learn more, check out the short video, consider subscribing,
Why AT&T Stock Climbed Today
Shares of AT&T (NYSE: T) popped on Wednesday after the telecommunications titan announced strong subscriber growth metrics.
By the close of trading, AT&T's stock price was up more than 4%.
Image
Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.
Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, with a market cap of around $950 billion. In the past five years, the stock price has soared an incredible 400%, thanks in
This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years
It's been a miserable past three years for Pfizer (NYSE: PFE) shareholders. Although this drugmaker's stock was all the rage in the early days of the COVID-19 pandemic, as it co-created a
Stock Market Today, Jan. 28: AT&T Rises After Earnings Beat and New Buyback Plan
AT&T (NYSE:T), a provider of wireless voice and data services, broadband, and digital television, closed Wednesday at $24.08, up 4.70%. The stock moved higher after Q4 results beat EPS and revenue
Why AbbVie Stock Trounced the Market in 2025
One of the better-quality companies in the pharmaceutical sector, AbbVie (NYSE: ABBV) had a phenomenal year in 2025. Bolstered by numerous positive developments, the company maintained its
Why UnitedHealth Group Stock Just Bounced Back
Shares of UnitedHealth Group (NYSE: UNH) stock crashed nearly 20% yesterday after reporting a tiny sales miss in its Q4 earnings report -- and a gigantic disappointment on profits.
Although
How Harmony Biosciences Can Prove Its Skeptics Wrong
Harmony Biosciences (NASDAQ: HRMY) is a rarity in the biopharmaceutical industry. Despite enjoying fast growth rates and being increasingly profitable for several years, Harmony trades at valuations
Here Are the 2 Headwinds Driving UnitedHealth's 20% Decline
UnitedHealth Group (NYSE: UNH) faced a number of challenges in 2025 that weighed on stock performance: from the higher costs of healthcare, which hurt earnings, to a Justice Department probe into
Stock Market Today, Jan. 27: UnitedHealth Group Plunges Almost 20% After Weak Earnings
UnitedHealth Group (NYSE:UNH), a major provider of health insurance and healtchare services, closed Tuesday at $282.69, down 19.61%. The stock sold off after Q4 results showed plunging operational
Is UnitedHealth Stock a No-Brainer Buy Again Under $300?
In this video, I will cover UnitedHealth Group's (NYSE: UNH) recent quarterly results and explain why the stock tanked. Watch the short video to learn more, consider subscribing, and click the
2 Biotech Stocks Set to Rebound in 2026
Looking to beat the market over the next five years? Here's one strategy to adopt: Invest in stocks that have not performed well recently but boast attractive prospects.
Two intriguing corporations
Why UnitedHealth Group Stock Just Crashed
Shares of health insurance giant UnitedHealth Group (NYSE: UNH) stock imploded this morning, falling 19% through 11 a.m. ET after reporting Q4 earnings. The weird thing is... UnitedHealth didn't
VALBIOTIS SA: 2025 Commercial roll-out underway, reflected in a strong ramp-up in revenues in Q4
2 Pharmaceutical Stocks Set to Rebound in 2026
The healthcare sector lagged broader equities last year. Novo Nordisk (NYSE: NVO) and Merck (NYSE: MRK), two pharmaceutical leaders, were among the underperformers. But here's the good news: There



